New Antifungal Drug Shows Promise for Aspergillosis
Adults with invasive aspergillosis may soon have an oral treatment option following successful Phase 3 trial results.
Updated on Oct. 21, 2026 in Diseases — General
Live Poll
Do you support the development of novel antifungal medications for patients with limited treatment options?
F2G and Shionogi have released Phase 3 trial results for the investigational antifungal drug olorofim, which showed non-inferiority to standard treatments for invasive aspergillosis. This development offers a potential new oral option for patients facing drug resistance or treatment intolerance.
Why it matters
Invasive aspergillosis is a serious fungal infection, and this trial specifically addresses patients who have failed or are unable to tolerate current standards of care. These results provide an alternative pathway for managing difficult-to-treat infections.
In a Phase 3 randomized trial of 225 adults with invasive aspergillosis, olorofim achieved non-inferiority to the control treatment of intravenous AmBisome plus standard of care. The mortality rate at Day 42 was 23.8% for the olorofim group compared to 24.3% for the control group.
The players
F2G
A Manchester-based biotechnology company focused on developing novel antifungal treatments.
Shionogi
An Osaka-based pharmaceutical company that researches treatments for infectious diseases.
The details
Olorofim is an investigational oral antifungal medication designed to inhibit fungal growth in patients where azole resistance or drug-drug interactions hinder current therapies. Participants were randomized 2:1 to receive up to 84 days of oral olorofim or intravenous AmBisome, with olorofim patients seeing an average hospital discharge time of 17 days compared to 28 days for the control group. Additionally, drug-related adverse events were reported in 35.8% of the olorofim arm, compared to 63.9% in the control group.
Timeline
October 21, 2026: F2G and Shionogi announced the OASIS study results.
October 22, 2026: Study results were presented at IDWeek 2026.
End of 2026: F2G plans to resubmit an NDA to the FDA.
Health Landscape
The presentation of the OASIS study at the IDWeek annual scientific meeting highlights the ongoing clinical efforts to address rising rates of antifungal resistance. This trial updates the existing standard of care by introducing a potential oral therapy for complex invasive infections.
For patients currently struggling with invasive aspergillosis due to medication resistance or intolerance, these findings represent an important development in future care options. Discussing potential trial-based therapies and emerging clinical options with an infectious disease specialist is recommended.
The takeaway
Olorofim provides a promising oral alternative for invasive aspergillosis cases that do not respond to traditional antifungal standards. Patients managing chronic or complex infections should consult their physician regarding ongoing clinical trials or upcoming regulatory approvals for new medications.
What happens next
F2G plans to resubmit a New Drug Application to the FDA by the end of 2026, following the release of the phase 3 data.
Further reading
For more information on the management of fungal infections, visit Diseases — General.
More information
For more information, visit the Shionogi website inquiry form.
Live Poll
Do you support the development of novel antifungal medications for patients with limited treatment options?
